Publications by authors named "Jean Philippe Claudel"
Article Synopsis
- A study analyzed data from French TAVR registries to compare long-term outcomes in patients using direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) after transcatheter aortic valve replacement (TAVR).
- The research found that patients on DOACs experienced lower mortality and major bleeding rates after three years compared to those on VKAs, although rates of ischemic events were similar between the two groups.
- The findings suggest that DOACs may be the preferred choice for oral anticoagulation therapy in TAVR patients, promoting better long-term safety and efficacy.
Objectives: This study sought to describe the procedural and clinical outcomes of patients undergoing transcarotid (TC) transcatheter aortic valve replacement (TAVR) with the Edwards Sapien 3 device.
Background: The TC approach for TAVR holds the potential to become the optimal alternative to the transfemoral gold standard. Limited data exist regarding safety and efficacy of TC-TAVR using the Edwards Sapien 3 device.
Background: The FRANCE-2 registry (French Aortic National Corevalve and Edwards) previously reported good early- and medium-term clinical and echocardiographic efficacy for transcatheter aortic valve replacement. We here report 5-year follow-up results from the registry.
Methods: The registry includes all consecutive patients undergoing transcatheter aortic valve replacement for severe aortic stenosis in France.
Background: Transcatheter aortic valve replacement (TAVR) is standard therapy for patients with severe aortic stenosis who are at high surgical risk. However, national data regarding procedural characteristics and clinical outcomes over time are limited.
Objectives: The aim of this study was to assess nationwide performance trends and clinical outcomes of TAVR during a 6-year period.
Background: Transcatheter aortic valve replacement (TAVR) has revolutionized management of high-risk patients with severe aortic stenosis. However, survival and the incidence of severe complications have been assessed in relatively small populations and/or with limited follow-up.
Objectives: This report details late clinical outcome and its determinants in the FRANCE-2 (FRench Aortic National CoreValve and Edwards) registry.
Background: Dual antiplatelet therapy, comprising aspirin and clopidogrel, is recommended in patients undergoing coronary stenting to avoid the occurrence of stent thrombosis and others ischaemic events. Interindividual response to clopidogrel varies, however, with poor response associated with an increased risk of ischaemic events. New assays are available for testing aspirin and clopidogrel response routinely at the bedside.
View Article and Find Full Text PDFBackground: Transcatheter aortic-valve implantation (TAVI) is an emerging intervention for the treatment of high-risk patients with severe aortic stenosis and coexisting illnesses. We report the results of a prospective multicenter study of the French national transcatheter aortic-valve implantation registry, FRANCE 2.
Methods: All TAVIs performed in France, as listed in the FRANCE 2 registry, were prospectively included in the study.